Aequus Pharmaceuticals Inc (AQS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.003x

Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-21.22K ≈ $-15.35K USD) by net assets (CA$-6.89 Million ≈ $-4.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aequus Pharmaceuticals Inc net asset quality index to measure how much of total assets are equity-financed.

Aequus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Aequus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Aequus Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.

Aequus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Foncière 7 investissement Société Anonyme PA:LEBL	0.140x
Revolution Beauty Group PLC LSE:REVB	0.074x
Craven House Capital PLC LSE:CRV	0.000x
CENTAURUS ENERGY INC. F:72M0	-0.044x
Digital 9 Infrastructure PLC LSE:DGI9	-0.027x
Helium One Global Ltd LSE:HE1	-0.001x
Zapp Electric Vehicles Group Limited Ordinary Shares NASDAQ:ZAPP	0.000x
Vicarious Surgical Inc. NYSE:RBOT	-0.740x

Annual Cash Flow Conversion Efficiency for Aequus Pharmaceuticals Inc (2013–2024)

The table below shows the annual cash flow conversion efficiency of Aequus Pharmaceuticals Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Aequus Pharmaceuticals Inc stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$-6.45 Million ≈ $-4.67 Million	CA$-1.66 Million ≈ $-1.20 Million	0.257x	-51.98%
2023-12-31	CA$-4.29 Million ≈ $-3.11 Million	CA$-2.29 Million ≈ $-1.66 Million	0.534x	-62.24%
2022-12-31	CA$-1.38 Million ≈ $-998.30K	CA$-1.95 Million ≈ $-1.41 Million	1.415x	+315.94%
2021-12-31	CA$1.79 Million ≈ $1.29 Million	CA$-1.17 Million ≈ $-847.96K	-0.655x	+53.28%
2020-12-31	CA$573.95K ≈ $415.19K	CA$-804.91K ≈ $-582.26K	-1.402x	-175.50%
2019-12-31	CA$-877.09K ≈ $-634.48K	CA$-1.63 Million ≈ $-1.18 Million	1.857x	+221.37%
2018-12-31	CA$1.68 Million ≈ $1.22 Million	CA$-2.57 Million ≈ $-1.86 Million	-1.530x	+7.45%
2017-12-31	CA$2.31 Million ≈ $1.67 Million	CA$-3.81 Million ≈ $-2.76 Million	-1.654x	+53.13%
2016-12-31	CA$1.27 Million ≈ $915.58K	CA$-4.47 Million ≈ $-3.23 Million	-3.528x	-18.07%
2015-12-31	CA$1.28 Million ≈ $929.30K	CA$-3.84 Million ≈ $-2.78 Million	-2.988x	-539.59%
2014-12-31	CA$2.92 Million ≈ $2.11 Million	CA$-1.36 Million ≈ $-987.33K	-0.467x	+85.04%
2013-12-31	CA$280.60K ≈ $202.98K	CA$-876.06K ≈ $-633.73K	-3.122x	--

About Aequus Pharmaceuticals Inc

V:AQS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$479.73K

CA$663.17K CAD

Market Cap Rank

#30936 Global

#1646 in Canada

Share Price

CA$0.01

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.01

All Time High

CA$0.69